Why Vectura group plc and GlaxoSmithKline plc could be the perfect combination

GlaxoSmithKline plc (LON: GSK) and Vectura Group plc (LON: VEC) have many complementary qualities.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in Vectura (LSE: VEC) are charging higher today after the company issued an upbeat trading statement ahead of its AGM to be held later today. The company reported stronger than expected trading and raised revenue expectations for the nine months to December 31.

Vectura is one of the London market’s greatest pharmaceutical success stories. The company’s growth has been explosive over the past few years and after merging with peer Skyepharma in June, the enlarged group is now poised to become a significant player in the industry. Sales across all of the company’s product lines are expanding at a high double-digit rate, and the group has a number of new treatments under development to further growth. Indeed, within today’s update Vectura revealed that sales for its Fruitform product for the six months ended June 30 were 42% ahead of the same period a year earlier at €92.4m from €65.1m a year earlier.

City analysts have been expecting Vectura to report earnings per share of 4.9p this year, putting the group on a forward P/E of 32.5 — these figures haven’t yet been adjusted to reflect today’s optimistic trading statement. At the end of 2015, the company reported a cash balance of £90m before the all-share merger with Skyepharma, which works out at around 10.8p per share.

Vectura’s earnings are growing rapidly, but the company’s premium valuation may put some investors off. If you’re wary of including Vectura in your portfolio, combining it with larger peer GlaxoSmithKline may be the perfect solution.

Old dog, new tricks? 

GlaxoSmithKline (LSE: GSK)  seems to be a love/hate stock. On the one hand, there are those who love the company for its above-average dividend yield and defensive nature. But on the other hand, many are worried about Glaxo’s patent cliff, which has already started to impact sales and income.

Last year Glaxo’s exclusive manufacturing patent for Avodart expired. The treatment for an enlarged prostate gland was generating sales of $973m for the company at its peak in 2010. And next year, it’s expected that generic versions of Glaxo’s blockbuster Advair treatment will hit the market. Last year, Advair accounted for 13% of overall group sales.

Still, Glaxo is making progress towards replacing these lost revenues. For the first half of 2016, the company reported revenue growth of 6% at constant exchange rates with core operating profit up 14%. The company expects full-year core earnings per share to grow by 11% to 12% at constant exchange rates. City analysts have pencilled-in earnings per share growth of 27% for the year ending 31 December 2016 and growth of 6% for 2017. Both of these estimates factor-in sterling’s depreciation.

The perfect mix? 

Combining Vectura and Glaxo in your portfolio would give you a strong mix of income and growth. Glaxo’s shares currently support a dividend yield of 5% and trade at a forward P/E of 17. Meanwhile, Vectura’s earnings per share are set to grow by 56% next year to 7.7p, even though the company’s shares look expensive now, this kind of growth deserves a premium valuation.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline and Vectura. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

2 UK stocks with recovering profit margins

This writer considers a pair of UK stocks with very different share price trajectories following the pandemic. Would he buy…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Will Trump’s tariffs squeeze this FTSE 100 giant’s profits?

Our writer looks at how the latest news around US tariffs might impact FTSE 100 company Diageo. Should he be…

Read more »

Investing Articles

Up 95%, is this FTSE winner the best high-yield star for me to buy now?

Do we have to choose between share price growth and high-yield dividends? In this case, over the past year, it…

Read more »

Investing Articles

Up 140% and rocketing out of the FTSE 250! Is it too late for me to buy this red-hot stock?

Miniature war games hero Games Workshop has outgrown the FTSE 250 and is hammering at the door of the UK's…

Read more »

Investing Articles

If I invest £10,000 in Taylor Wimpey shares, how much passive income will I receive?

Taylor Wimpey shares have fallen and are now paying a huge dividend. How much might I receive by investing a…

Read more »

Index Funds text carved in stone background
Investing Articles

Why I choose to invest in individual stocks rather than an index fund

Our writer examines the differences between stock picking and investing in index funds and why he feels there’s more to…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Here’s the dividend forecast for Sage Group shares through to 2026!

The dividend on Sage shares has risen for 12 straight years. Can the FTSE 100 company keep its proud record…

Read more »

Happy African American Man Hugging New Car In Auto Dealership
Investing Articles

Will 2025 be make or break for this FTSE 250 stock hitting the headlines?

One of the FTSE 250's worst performers in 2024 has just issued another profit warning, but could 2025 mark the…

Read more »